Utilizing Dexmedetomidine for Opioid-Resistant Pain and Anxiety in the Palliative Care Unit: A Case Report on Efficacy, Withdrawal Challenges, and Protocol Adaptations
Dexmedetomidine (Precedex™) has proved useful in palliating anxiety and intractable pain in patients at the end of life. However, abrupt cessation can precipitate withdrawal, which is highly unpleasant and potentially dangerous. Here, we present the case of a patient whose intractable pain was successfully palliated with a dexmedetomidine infusion but who then developed severe withdrawal when the infusion was stopped with a change in her plan of care. We present a review of the literature around transitioning patients off dexmedetomidine and highlight the need for more guidance on nonintensive care unit management of its side effects and alternatives.
Authors
- Rabia S. Atayee (ORCID: https://orcid.org/0000-0003-0505-8693)
- Matthew Mason (ORCID: https://orcid.org/0000-0001-5067-8272)
- Paula Mesarwi
- Karolina Soriano
- Paula Aragon
- Kyle P. Edmonds (ORCID: https://orcid.org/0000-0002-0790-5211)
- Jennifer M. Byrne
- Mindy M. Le
Institutions
- UC San Diego Health System (US)
- University of Montana (US)
Publication Details
- Journal
- Journal of Palliative Medicine
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1089/jpm.2025.0053
- Primary Topic
- Intensive Care Unit Cognitive Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00